Scientists probe why some melanoma patients respond to immunotherapy
NCT ID NCT02626065
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 32 people with advanced melanoma who were treated with the immunotherapy drug Nivolumab. Researchers took blood samples before and during treatment to track changes in immune cells. The goal was to find differences between patients whose tumors shrank or stayed stable and those whose cancer kept growing, which could lead to better treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab
What this could lead to
If successful, this could help doctors predict which melanoma patients will benefit from Nivolumab and improve treatment strategies.
What could go wrong
This is a small, completed study focused on understanding immune responses, not testing a new treatment. Results may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France